Soumettre la recherche
Mettre en ligne
Emerging Therapies For Dmd
•
Télécharger en tant que PPT, PDF
•
0 j'aime
•
400 vues
T
truthofe
Suivre
Signaler
Partager
Signaler
Partager
1 sur 20
Télécharger maintenant
Recommandé
Hecho por: Samuel Salazar Arango Laura Camila Sepulveda
Seminario Biología Molecular
Seminario Biología Molecular
SamuelSalazar39
The tumour suppressor and transcription factor p53 is a major determinant of the therapeutic response to anthracyclines. In healthy tissue, p53 is also considered pivotal for side effects of anthracycline treatment such as lesions in haematopoietic tissues like the spleen. We used a Trp53null mouse to explore the significance of p53 in anthracycline (daunorubicin) induced lesions in the spleen.
Functional p53 is required for rapid restoration of daunorubicin-induced lesi...
Functional p53 is required for rapid restoration of daunorubicin-induced lesi...
Enrique Moreno Gonzalez
Glioblastomas, the most common and malignant brain tumors of the central nervous system, exhibit high invasive capacity, which hinders effective therapy. Therefore, intense efforts aimed at improved therapeutics are ongoing to delineate the molecular mechanisms governing glioma cell migration and invasion.
CXCR7 is induced by hypoxia and mediates glioma cell migration towards SDF-1a...
CXCR7 is induced by hypoxia and mediates glioma cell migration towards SDF-1a...
Enrique Moreno Gonzalez
Triple Screen FINAL poster-3
Triple Screen FINAL poster-3
Whitney Best
Antisense oligonucleotides in therapy
Antisense oligoneucleotides in therapy
Antisense oligoneucleotides in therapy
Dr Sajeena Jose
SPLICING
SPLICING
Daniel Peña
Branch of Biology which studies causal interaction between genes and their products, which bring the phenotype in to being.
Exploring the role of Epigenetic regulation in plant disease management
Exploring the role of Epigenetic regulation in plant disease management
VigneshVikki10
Xiaoming (Sherman) Jia, MD MEng ACTRIMS-ECTRIMS MSParis2017 Platform Presentation, Oct 27, 2017.
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Sherman Jia
Recommandé
Hecho por: Samuel Salazar Arango Laura Camila Sepulveda
Seminario Biología Molecular
Seminario Biología Molecular
SamuelSalazar39
The tumour suppressor and transcription factor p53 is a major determinant of the therapeutic response to anthracyclines. In healthy tissue, p53 is also considered pivotal for side effects of anthracycline treatment such as lesions in haematopoietic tissues like the spleen. We used a Trp53null mouse to explore the significance of p53 in anthracycline (daunorubicin) induced lesions in the spleen.
Functional p53 is required for rapid restoration of daunorubicin-induced lesi...
Functional p53 is required for rapid restoration of daunorubicin-induced lesi...
Enrique Moreno Gonzalez
Glioblastomas, the most common and malignant brain tumors of the central nervous system, exhibit high invasive capacity, which hinders effective therapy. Therefore, intense efforts aimed at improved therapeutics are ongoing to delineate the molecular mechanisms governing glioma cell migration and invasion.
CXCR7 is induced by hypoxia and mediates glioma cell migration towards SDF-1a...
CXCR7 is induced by hypoxia and mediates glioma cell migration towards SDF-1a...
Enrique Moreno Gonzalez
Triple Screen FINAL poster-3
Triple Screen FINAL poster-3
Whitney Best
Antisense oligonucleotides in therapy
Antisense oligoneucleotides in therapy
Antisense oligoneucleotides in therapy
Dr Sajeena Jose
SPLICING
SPLICING
Daniel Peña
Branch of Biology which studies causal interaction between genes and their products, which bring the phenotype in to being.
Exploring the role of Epigenetic regulation in plant disease management
Exploring the role of Epigenetic regulation in plant disease management
VigneshVikki10
Xiaoming (Sherman) Jia, MD MEng ACTRIMS-ECTRIMS MSParis2017 Platform Presentation, Oct 27, 2017.
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Sherman Jia
ANTISENSE USED AS AN DRUG IN FUTURE
Antisense oligonucleotide therapy
Antisense oligonucleotide therapy
ROHIT
Antisense technic for the treatment of diseases. Mechanism of action of the antisense oligonucleotide.
Antisense technologies and antisense oligonucleotides
Antisense technologies and antisense oligonucleotides
RangnathChikane
by group 4: Lim Chloe, Wai Kai Wen, Tan Poh Hui, Woo Xue Rou
Treatment for lysosomal storage diseases using crispr cas9
Treatment for lysosomal storage diseases using crispr cas9
limchloe
Présentation de Michel Pucéat réalisée durant le cours du réseau international des instituts Pasteur de "Médecine Génomique: du diagnostic à la thérapie " (17-21 octobre 2016)
Epigenetic regulation of cardiogenesis
Epigenetic regulation of cardiogenesis
Pasteur_Tunis
DOORS
DOOR syndrome
DOOR syndrome
Satrupa Das
1506.full
1506.full
Elsa von Licy
Bio 1
Bio 1
BioinformaticsInstitute
Debate in favor of Bortezomib as standard of care for myeloma. By panisinee lawasut
Bortezomib as standard of care for multiple myeloma
Bortezomib as standard of care for multiple myeloma
spa718
Plegable
Plegable
SaraOcampo
Austin Transplantation Sciences is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Transplantation Sciences. The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Transplantation Sciences. Austin Transplantation Sciences accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of Transplantation Sciences. Austin Transplantation Sciences strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
Austin Transplantation Sciences
Austin Transplantation Sciences
Austin Publishing Group
JC paper-2009
JC paper-2009
Nisha Rizvi
NAGLU_IGF2 ERT in mouse
NAGLU_IGF2 ERT in mouse
Shih-hsin Kan
ANTISENSE THERAPHY
ANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDES
ayanarkumar19
DNA methylation
DNA methylation
Sahar Sajadian
11 orlowski lunch-symposium_final
11 orlowski lunch-symposium_final
spa718
hinckley poster5 (2)
hinckley poster5 (2)
Sj Afshari
Viral in hemat
Viral in hemat
Joydeep Ghosh
in this presentation the molecular markers which are used to detect the muscular dystrophy was described.
molecular markers in muscular dystrophy
molecular markers in muscular dystrophy
Malar Malar
Esnrt poster cd20
Esnrt poster cd20
Esnrt poster cd20
FarragBahbah
NỘI TIẾT
Medullary thyroid carcinoma
Medullary thyroid carcinoma
SoM
Power Point presentation for Work Place Giving program
Work Place Giving
Work Place Giving
Save Our Sons Taylor
Session 17 kate_bushby
Session 17 kate_bushby
EURORDIS - Rare Diseases Europe
Contenu connexe
Tendances
ANTISENSE USED AS AN DRUG IN FUTURE
Antisense oligonucleotide therapy
Antisense oligonucleotide therapy
ROHIT
Antisense technic for the treatment of diseases. Mechanism of action of the antisense oligonucleotide.
Antisense technologies and antisense oligonucleotides
Antisense technologies and antisense oligonucleotides
RangnathChikane
by group 4: Lim Chloe, Wai Kai Wen, Tan Poh Hui, Woo Xue Rou
Treatment for lysosomal storage diseases using crispr cas9
Treatment for lysosomal storage diseases using crispr cas9
limchloe
Présentation de Michel Pucéat réalisée durant le cours du réseau international des instituts Pasteur de "Médecine Génomique: du diagnostic à la thérapie " (17-21 octobre 2016)
Epigenetic regulation of cardiogenesis
Epigenetic regulation of cardiogenesis
Pasteur_Tunis
DOORS
DOOR syndrome
DOOR syndrome
Satrupa Das
1506.full
1506.full
Elsa von Licy
Bio 1
Bio 1
BioinformaticsInstitute
Debate in favor of Bortezomib as standard of care for myeloma. By panisinee lawasut
Bortezomib as standard of care for multiple myeloma
Bortezomib as standard of care for multiple myeloma
spa718
Plegable
Plegable
SaraOcampo
Austin Transplantation Sciences is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Transplantation Sciences. The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Transplantation Sciences. Austin Transplantation Sciences accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of Transplantation Sciences. Austin Transplantation Sciences strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
Austin Transplantation Sciences
Austin Transplantation Sciences
Austin Publishing Group
JC paper-2009
JC paper-2009
Nisha Rizvi
NAGLU_IGF2 ERT in mouse
NAGLU_IGF2 ERT in mouse
Shih-hsin Kan
ANTISENSE THERAPHY
ANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDES
ayanarkumar19
DNA methylation
DNA methylation
Sahar Sajadian
11 orlowski lunch-symposium_final
11 orlowski lunch-symposium_final
spa718
hinckley poster5 (2)
hinckley poster5 (2)
Sj Afshari
Viral in hemat
Viral in hemat
Joydeep Ghosh
in this presentation the molecular markers which are used to detect the muscular dystrophy was described.
molecular markers in muscular dystrophy
molecular markers in muscular dystrophy
Malar Malar
Esnrt poster cd20
Esnrt poster cd20
Esnrt poster cd20
FarragBahbah
NỘI TIẾT
Medullary thyroid carcinoma
Medullary thyroid carcinoma
SoM
Tendances
(20)
Antisense oligonucleotide therapy
Antisense oligonucleotide therapy
Antisense technologies and antisense oligonucleotides
Antisense technologies and antisense oligonucleotides
Treatment for lysosomal storage diseases using crispr cas9
Treatment for lysosomal storage diseases using crispr cas9
Epigenetic regulation of cardiogenesis
Epigenetic regulation of cardiogenesis
DOOR syndrome
DOOR syndrome
1506.full
1506.full
Bio 1
Bio 1
Bortezomib as standard of care for multiple myeloma
Bortezomib as standard of care for multiple myeloma
Plegable
Plegable
Austin Transplantation Sciences
Austin Transplantation Sciences
JC paper-2009
JC paper-2009
NAGLU_IGF2 ERT in mouse
NAGLU_IGF2 ERT in mouse
ANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDES
DNA methylation
DNA methylation
11 orlowski lunch-symposium_final
11 orlowski lunch-symposium_final
hinckley poster5 (2)
hinckley poster5 (2)
Viral in hemat
Viral in hemat
molecular markers in muscular dystrophy
molecular markers in muscular dystrophy
Esnrt poster cd20
Esnrt poster cd20
Medullary thyroid carcinoma
Medullary thyroid carcinoma
En vedette
Power Point presentation for Work Place Giving program
Work Place Giving
Work Place Giving
Save Our Sons Taylor
Session 17 kate_bushby
Session 17 kate_bushby
EURORDIS - Rare Diseases Europe
SWOT of my 4 Initial ideas
Swot
Swot
Tubamubashira
idea mapping for a documentary
Idea mapping
Idea mapping
Tubamubashira
Rare Disease Stakeholder Dynamics
Rare disease stakeholder dynamics pmrg institute fall 2014
Rare disease stakeholder dynamics pmrg institute fall 2014
azdybak
Medicine is at heart a narrative activity–the telling and receiving of story. The patient interview is based on the notion that the patient, as story-teller, will share his or her experience, and that the doctor, as active listener, will be able to take that story and make sense of it in the world of science and medicine. Health care is supposed to build on the story with each contact, but if we don’t know the story, each contact becomes a closed episode of its own, disconnected from every other episode. Fragmentation results as the outcome of a nonstoried approach to health care. In this workshop, we will explore how the ancient art of storytelling can foster an empathetic healthcare model and generate a framework for a more holistic approach to treating the patient, while at the same time providing a rich source of diagnostic clues. Narrative medicine represents a storied understanding of health. It’s a return to listening to the patient’s story. Doctors who are trained to listen to the story of the disease need to learn to listen also to the story of the illness. We’ll explore how to incorporate narrative medicine and storytelling into medical education
Teaching the Rx Narrative; Story as Medicine
Teaching the Rx Narrative; Story as Medicine
Marie Ennis-O'Connor
En vedette
(6)
Work Place Giving
Work Place Giving
Session 17 kate_bushby
Session 17 kate_bushby
Swot
Swot
Idea mapping
Idea mapping
Rare disease stakeholder dynamics pmrg institute fall 2014
Rare disease stakeholder dynamics pmrg institute fall 2014
Teaching the Rx Narrative; Story as Medicine
Teaching the Rx Narrative; Story as Medicine
Similaire à Emerging Therapies For Dmd
simple and easy
cancer nice paper.pdf
cancer nice paper.pdf
asthabisht789
Tuberous Sclerosis: Update in Diagnosis and Treatment
Tuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MD
NYU FACES
Cerullo_verona2010_AdenovirusGT
Cerullo_verona2010_AdenovirusGT
Vincenzo Cerullo
Access to Research Date 11-08-2018 Venue Conference HAll NIAS IISc campus Conference and workshops for clinical practitioners to introduce them to modern tools and an alternative approach to modern scientific research. Purpose 1. Build a network of physicians across the country 2 Train physicians to analyse clinical data and restructure it to make it compatible with research standards 3. Introduce modern tools to understand the mechanism of actions of medicine 4. Introduce artificial intelligence and machine learning to clinical practitioners to support decision-making processes Access to Science Clinical experience and traditional knowledge are important sources of data that affect decision making processes in modern healthcare systems. This data should be made accessible for scientific evaluation and validation to improve healthcare worldwide. The Open Source Pharma Foundation believes that clinical practitioners from various disciplines should have the right to access research so that they can help identify problems, contribute their scientific knowledge, and support the discovery ecosystem. Background The majority of medical practitioners working on the ground level with patients do not take part in open clinical research worldwide. However, the data collected and owned by them plays an important role in establishing better discovery pathways. Through this workshop, we seek to open opportunities to enhance health care systems around the world and to overcome the following challenges faced by medical practitioners. 1. Regulatory limitations 2. Academic limitations 3. Time constraints 4. Lack of access to modern tools 5. Lack of access to research facilities
Open Source Pharma /Genomics and clinical practice / Prof Hosur
Open Source Pharma /Genomics and clinical practice / Prof Hosur
opensourcepharmafound
nihms336576
nihms336576
Wan Lu Woo
Genetic information is stored in DNA by means of a triplet code that is nearly universal to all living things on Earth.
P53 apoptosis
P53 apoptosis
Anfal Izaldeen AL KATEEB
news and views
news and views
Maria Teresa Esposito
Sindrome di rett
Sindrome di rett
iva martini
Oncogene1.PDF
Oncogene1.PDF
Alexandre "Sasha" Nesterov
1.2 fpr
1.2 fpr
EURORDIS Rare Diseases Europe
Antisense therapy is presented by E,harika (13gd1r0013) from chilkur balaji college of pharmacy hyderabad,hyderabad
Antisense therapy
Antisense therapy
konatham teja kumar reddy
Notch1 inhibition enhances DNA damage induced by cisplatin in cervical cancer
Seminario biologia molecular- Maria Upegui
Seminario biologia molecular- Maria Upegui
isabellabuitrago4
TBI is the leading cause of death among young adults and children in the developed world, accounting for over 50,000 deaths per year. [12] TBI results in a sleuth of poor health outcomes, including hemorrhaging, seizures, neural edema, neural inflammation, and cognitive and emotional disabilities. All of these outcomes are a direct result of fundamental degradation of the BBB over a time course post TBI. [1] [12] The BBB is an integral structure that forms around the microvascular of the cerebral cavity. Endothelial cells form the basal membrane through which strictly controlled movement of molecules is observed between the extravascular and intravascular space across this basal membrane. This basal membrane is maintained by endothelial cells, having tight junctions between them to make up the pores through which transport of molecules can occur between the brain and microvasculature. These tight junctions are maintained through cross-talk between the endothelial cells and supporting neurons such as astrocytes and pericytes. [2] A multitude of proteins make up the tight junctions between the endothelial cells, including six main scaffolding structures Claudins 1, 3, and 5, ZO-1, Occludins, and Cadherins. [3] VEGF release following trauma induces endothelial cells to release matrix metalloproteinases (MMPs), in particular MMP9, which can catalyze the N-terminal amino acids that compose the tight junction protein ZO-1. [10] [11] MMP9 when in circulation is also known to activate tumor necrosis factor alpha (TNFɑ) which in turn upregulates transcription of MMP9, creating a positive feedback loop. [11] The management of MMP production is three fold, transcription, proenzyme activation, and substrate inhibition. [11] In our study, it is proenzyme activation via TP that is the focus and how that affects the overall transcription levels of the tight junction proteins within the endothelial cells and astrocytes.
Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...
Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...
Arthur Stem
Seminario biomol 2
Seminario biomol 2
therong
Symposium Presentation-Change in Transcriptome in Human Cells Deficient and P...
Symposium Presentation-Change in Transcriptome in Human Cells Deficient and P...
Usman Hyder
MSc dissertation
MSc dissertation
David Robinson
Gene Therapyrr
Gene Therapyrr
alaa essa
Bordet-JPET-2007
Bordet-JPET-2007
Bruno Buisson
Présentation de Radovan Komel réalisée durant le cours du réseau international des instituts Pasteur de "Médecine Génomique: du diagnostic à la thérapie " (17-21 octobre 2016)
Functional analysis of proteomic biomarkers and targeting glioblastoma stem c...
Functional analysis of proteomic biomarkers and targeting glioblastoma stem c...
Pasteur_Tunis
Dr Rusnawati Yahya Consultant Nephrologist Hospital Kuala Lumpur
Membranous Nephropathy
Membranous Nephropathy
edwinchowyw
Similaire à Emerging Therapies For Dmd
(20)
cancer nice paper.pdf
cancer nice paper.pdf
Tuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MD
Cerullo_verona2010_AdenovirusGT
Cerullo_verona2010_AdenovirusGT
Open Source Pharma /Genomics and clinical practice / Prof Hosur
Open Source Pharma /Genomics and clinical practice / Prof Hosur
nihms336576
nihms336576
P53 apoptosis
P53 apoptosis
news and views
news and views
Sindrome di rett
Sindrome di rett
Oncogene1.PDF
Oncogene1.PDF
1.2 fpr
1.2 fpr
Antisense therapy
Antisense therapy
Seminario biologia molecular- Maria Upegui
Seminario biologia molecular- Maria Upegui
Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...
Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...
Seminario biomol 2
Seminario biomol 2
Symposium Presentation-Change in Transcriptome in Human Cells Deficient and P...
Symposium Presentation-Change in Transcriptome in Human Cells Deficient and P...
MSc dissertation
MSc dissertation
Gene Therapyrr
Gene Therapyrr
Bordet-JPET-2007
Bordet-JPET-2007
Functional analysis of proteomic biomarkers and targeting glioblastoma stem c...
Functional analysis of proteomic biomarkers and targeting glioblastoma stem c...
Membranous Nephropathy
Membranous Nephropathy
Emerging Therapies For Dmd
1.
Sriharsha Gowtham
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Télécharger maintenant